Atopic dermatitis (eczema) has moved beyond steroid creams and constant flares with the arrival of dupilumab and other biologics, plus new JAK inhibitor pills and creams. For moderate-to-severe disease, many patients now go from constant itching to clear skin, often within weeks.
What's actually going on in research
Trials are testing newer biologic injections targeting IL-13, IL-31 (the itch cytokine), and OX40, oral JAK inhibitors, and topical treatments for milder disease. Researchers are also studying eczema in infants and children, the link with food allergies and asthma, and approaches to prevent eczema in babies at high risk.
Biologic injections
Drugs like dupilumab and tralokinumab clear skin and stop the itch for many patients with moderate-to-severe eczema. Newer biologics target additional cytokines.
Oral JAK inhibitors
Pills like upadacitinib and abrocitinib quickly reduce itch and clear skin, often within days. They are alternatives for people who prefer pills or have failed biologics.
Itch-targeted drugs
Anti-IL-31 antibodies like nemolizumab specifically target the itch pathway, helping people whose itch persists even when skin looks better.
What to know before you search
Eligibility often depends on severity, body surface area affected, age, prior treatments, and other allergic conditions like asthma or food allergy.
What types of trials are currently open
- New medication trials — Testing biologic injections and oral drugs for moderate-to-severe eczema.
- Topical trials — Testing newer creams and ointments for eczema, including non-steroidal options.
- Pediatric trials — Testing treatments specifically in infants, children, and teens with eczema.
- Prevention trials — Testing whether early skin care or food introduction prevents eczema and food allergies in high-risk babies.
- Observational studies — Following people with eczema to understand triggers, allergies, and long-term outcomes.
Recently added Atopic Dermatitis trials
Assessment of cfDNA-STING Axis as a Potential Pathological Marker in Atopic Dermatitis
Study Overview Atopic dermatitis (AD), commonly known as eczema, is a chronic inflammatory skin condition characterized by intense itching and skin barrier damage. While researchers know that the immune system is overactive in AD, it is difficult to measure the exact level of "damage" or "inflammation" happening deep within the skin using only a physical exam. The Purpose of This Study This study investigates a specific "danger signal" called circulating cell-free DNA (cfDNA). When skin cells are damaged or die due to inflammation, they release tiny fragments of DNA into the bloodstream. We believe these fragments might act as a trigger for the immune system, worsening the disease. What the Study Involves Researchers will collect blood samples and small skin biopsies from patients with AD and healthy volunteers. The study aims to: Compare the levels of cfDNA in the blood of AD patients versus healthy individuals. Determine if higher levels of cfDNA correlate with more severe skin symptoms (measured by scores like SCORAD and EASI). Examine how immune cells in the skin (macrophages) respond to these DNA fragments through a specific biological switch called the STING pathway. Potential Impact By understanding this "damage-signal" loop, this research may lead to new ways for doctors to monitor AD severity through simple blood tests and could identify new targets for future anti-inflammatory treatments.
Evaluation by Confocal Reflectance Microscopy of the Skin Structure of Patients With Atopic Dermatitis Treated With Tralokinumab Biotherapy.
Atopic dermatitis (AD) is a chronic inflammatory skin disease with pruritus and recurrence of eczematous eruptions. Evaluation of response to treatment are only clinical using Eczema Area Severity Index (EASI), SCOring of Atopic Dermatitis Index (SCORAD) scores, with a risk of intra-observer variations. Tralokinumab is a fully human anti-IL-13 monoclonal antibody that has proven to be effective and well-tolerated for the treatment of patients with moderate-to-severe AD. Reflectance confocal microscopy (RCM) is a noninvasive procedure that allows to evaluate epidermis and papillary dermis at a cellular level. RCM allows skin structural and inflammatory parameters evaluation. The aim of this study is to evaluate by RCM skin modifications of AD patients treated with tralokinumab.
Find Atopic Dermatitis trials matched specifically to you
Answer 3 quick questions and we'll show you trials that fit your situation.